The FDA’s decision to grant RMAT designation to KB707 reflects both the urgent unmet need for new NSCLC therapies as well as the promising early clinical evidence of efficacy we have observed with ...

A new randomized clinical trial showed that receiving immunochemotherapy infusions earlier in the day may help patients with ...

Zipalertinib showed a 35% overall response rate in EGFR exon 20 mutated NSCLC, with notable CNS activity and a favorable safety profile. NeoADAURA trial highlighted the feasibility of neoadjuvant EGFR ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced Medicare coverage for the company’s NeXT Personal molecular residual disease (MRD) test for ...

University of Queensland researchers who mapped cancer cell "neighborhoods" in the most common type of lung cancer have found ...

Sunvozertinib is the first targeted oral treatment for NSCLC with EGFR exon 20 insertion mutations, approved for post-chemotherapy progression cases. The WU-KONG1 Part B study showed a 53.3% objective ...

Survivors of non-small cell lung cancer are at risk for both second primary lung cancers as well as non-lung secondary ...

Small cell lung cancer (SCLC) is a fast-growing cancer that forms in the lung. It's one of two types of lung cancer. The other type is non-small cell lung cancer (NSCLC). SCLC is less common than ...

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...

Investing.com -- Personalis Inc (NASDAQ:PSNL) stock jumped 9.3% Tuesday after the precision oncology company announced Medicare coverage for its NeXT Personal molecular residual disease test for ...

Personalis shares rose after the company received Medicare coverage for its NeXT Personal molecular residual disease test for surveillance of patients with Stage I to III non-small cell lung cancer.

Hernexeos (zongertinib) received FDA accelerated approval for unresectable or metastatic non-squamous NSCLC with HER2 TKD mutations after prior treatment. The Beamion LUNG-1 trial showed a 75% ...